PHF14 and neoplasm: Furthermore, administration of Sunitinib (40 or 80 mg/kg) by oral gavage profoundly inhibited tumor growth (Figure 5C) with greater tumor suppression observed in mice harboring the PHF-14 knockout sgRNA cells (tumor weight (g); control, Vehicle: 0.32 ± 0.27; Sunitinib 40 mg/kg: 0.06 ± 0.029, p < 0.01; Sunitinib 80 mg/kg: 0.071 ± 0.039, p < 0.01 versus sgRNA-PHF14, Vehicle: 0.61 ± 0.45; Sunitinib 40 mg/kg: 0.083 ± 0.071 p < 0.05, Sunitinib 80 mg/kg: 0.041 ± 0.043, p < 0.05, Figure 5D).